7 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Sanotize Research and Development corp.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis Nitric Oxide - Candidiasis, Oral | Phase 1 | Completed | Sanotize Research and Development corp. | 6 | 2024-01-20 | 2024-07-10 |
| Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis Nitric Oxide Releasing Solution, Nasal spray with isotonic saline - Recurrent Acute Rhinosinusitis | Phase 2 | Completed | Sanotize Research and Development corp. | 162 | 2024-01-16 | 2026-04-22 |
| Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) Sterile water foot bath, Nitric Oxide - Verruca Plantaris | Phase 2 | Completed | Sanotize Research and Development corp. | 20 | 2023-08-02 | 2024-04-17 |
| Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection Nitric Oxide, Nasal spray with isotonic saline - SARS-CoV-2 Infection | Phase 3 | Terminated | Sanotize Research and Development corp. | 1389 | 2021-11-20 | 2025-09-25 |
| Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19 Nitric Oxide - SARS-CoV-2 Infection | Phase 3 | Completed | Sanotize Research and Development corp. | 306 | 2021-11-01 | 2022-10-31 |
| Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers Nitric Oxide-Releasing Solution, Saline solution, hypotonic - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Completed | Sanotize Research and Development corp. | 40 | 2021-02-23 | 2023-05-31 |
| Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection Nitric Oxide-Releasing Drug - SARS-CoV Infection | Phase 2 | Withdrawn | Sanotize Research and Development corp. | 2021-01-01 | 2021-07-16 | |
| Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection NORS (Nitric Oxide Releasing Solution) - Corona Virus Infection | Phase 2 | Completed | Sanotize Research and Development corp. | 143 | 2020-05-08 | 2021-02-10 |
| Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS) Nitric Oxide, Budesonide - Chronic Sinusitis | Phase 2 | Completed | Sanotize Research and Development corp. | 56 | 2019-10-27 | 2022-06-30 |
COVID-19 (2) · Sinusitis (2) · Candidiasis, Oral (1) · Coronavirus Infections (1) · Diabetic Foot (1) · Recurrence (1) · Rhinosinusitis (1) · Severe Acute Respiratory Syndrome (1) · Warts (1)
Nitric Oxide (6) · Nasal Sprays (2) · Budesonide (1) · Saline Solution (1) · Therapeutics (1) · noggin protein (1)
Canada (7) · India (1) · Sri Lanka (1)
Keith Moore, PHARMD (2) · Keith Moore, PHARMMD (2) · Amin Javer, MD (1) · Chris Miller, Ph.D (1) · Jeremy Road, MD (1) · Joel Epstein (1) · Keith Moore, PharmD (1) · Scott Schumacher, MD (1)